CERo Therapeutics issues $937.5k convertible note, dismisses auditor Wolf & Co., appoints Eric Francois to board

CERO THERAPEUTICS HOLDINGS, INC.

Issued $937,500 convertible note to Keystone Capital Partners at $750,000; 10% interest, matures July 2027, convertible at discount to market.
Dismissed Wolf & Company, P.C. as auditor effective Feb 13, 2026; no disagreements, but prior material weakness in internal controls noted.
Appointed Salberg & Company, P.A. as new auditor effective Feb 13, 2026.
Appointed Eric Francois to board, increasing size to 7; he served as Managing Director at Raymond James, CFO at Scynexis.

item 1.01item 2.03item 3.02item 4.01item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.